Considerations for COVID-19 Revaccination

Recipients of hematopoietic cell transplantation (HCT) or chimeric antigen receptor (CAR) T-cell therapy who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated.

• Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule.

Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies).

• The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy.

Reference: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#considerations-COVID-19-revaccination